Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$812,380
-$2,664,417 QoQ
Shares Held
469,584
-8.0% QoQ
Ownership
0.701%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#20
of 60 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Eversept Partners, LP holds $859,319,346 across 72 Biotechnology names. ENGN ranks #65 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
913,880 | $121,783,648 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,212,770 | $94,949,960 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
1,785,941 | $66,454,864 | |
| 4 | SNDX |
Syndax Pharmaceuticals Inc
|
2,798,210 | $61,168,870 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
664,684 | $52,702,794 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
798,973 | $45,389,656 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
629,952 | $36,619,109 | |
| 8 | GERN |
Geron Corp
|
18,717,422 | $23,958,300 |
All Filings in ENGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $812,380 | 469,584 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $3,476,797 | 510,543 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,116,190 | 455,835 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||